Key Retreatment Decisions in the Clinical Trials for Faricimab in nAMD

Video

Dr Varun Chaudhary presents the retreatment decisions during the treat-and-extend phase of the TENAYA and LUCERNE clinical trials in neovascular AMD, focusing on the percentage of patients who maintained, extended, or reduced their treatment interval based on visual and anatomic criteria.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
Two hands reach towards a logo which says "AI," for artificial intelligence. Concept image for AI screenings for neovascular age-related macular degeneration. Image credit: ©deagreez – stock.adobe.com

Artificial intelligence analyses biomarker changes in neovascular AMD treated with faricimab

Lynda Charters
April 17th 2025
Article

The phase 3 LUCERNE and TENAYA trials suggested that faricimab may allow clinicians to extend the interval between injections to up to 16 weeks after an initial loading phase

An image which shows a translucent head, with the eye, brain and optic nerve highlighted. Concept for brain-eye neurology neuroinflammation connection. Image credit: ©jitendra jadhav – stock.adobe.com

Journal of Neuroinflammation publishes data on Eleva’s lead retinal asset CPV-104

Sydney M Crago
April 16th 2025
Article

In an established animal model of age-related macular degeneration, Eleva’s recombinant human CPV-104 improved two hallmarks of the disease

A scientist in a lab looks into a microscope, which is placed on a desk. His face is not fully visible but he wears a lab coat and sits in front of a computer. Concept image for cell therapy, stem cell research, phase 1 clinical trial, and geographic atrophy associated with age-related macular degeneration. Image credit: ©CoetzeeRising/peopleimages.com – stock.adobe.com

Eyestem Research announces positive results from phase 1 geographic atrophy trial

Martin David Harp
April 14th 2025
Article

Bangalore-based Eyestem will share more research findings on Eyecyte-RPE at this year's Association for Research in Vision and Ophthalmology meeting

An image of a person pressing a computer shutdown button, superimposed digitally over the image. Concept for clinical trial discontinuation. Image credit: ©natali_mis – stock.adobe.com

Opthea discontinues COAST and ShORe sozinibercept combination therapy trials

Martin David Harp
April 2nd 2025
Article

Both trials failed to meet their primary endpoints for treatment of age-related macular degeneration

An elderly man and his caregiver discuss their budget and financial well-being. Concept image for caretaker, caregiver, aging, age-related macular degeneration. Image credit: ©Andrii Lysenko – stock.adobe.com

International study illuminates economic burden of late-stage age-related macular degeneration

Lynda Charters
March 31st 2025
Article

Researchers assessed the costs to patients and caregivers in Germany, Bulgaria and the US

Two boxes, labeled "yes" and "no." There is a red checkmark in the "no" box. Concept portraying an ophthalmic clinical trial which does not meet its endpoint. Image credit: ©Matthew Benoit – stock.adobe.com

Phase 3 COAST trial fails to meet primary endpoints for wet AMD, Opthea reports

Martin David Harp
March 24th 2025
Article

The Combination OPT-302 with Aflibercept Study (COAST) evaluated sozinibercept 2 mg in combination with aflibercept 2 mg for wet age-related macular degeneration

© 2025 MJH Life Sciences

All rights reserved.